Faculty Opinions recommendation of Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Keyword(s):
Phase 2
◽
2015 ◽
Vol 30
(2)
◽
pp. 216-224
◽
2015 ◽
Vol 30
(9)
◽
pp. 1717-1725
◽